🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Comparison is the thief of joy. I have not found a saying more true in the field of medicine than this one.

Headed to Chicago for #ASCO23! We have some amazing presentations on the agenda you won’t want to miss. Keep up with us for the details! Safe travels to all attending. Dr. Nina Niu Sanford Vishnu Venkatesh Heather McArthur, MD, MPH, FASCO Amy Little Jones, MD Mir Lim Naveen Premnath Sheena Bhalla Tian Zhang, MD, MHS

azolifesciences.com/news/20230623/…

Very happy to be partnering with UT Southwestern Medical Center to provide our #NutritionEducation course to medical students in the ambulatory clerkship program! Welcome to those students who begin their nutrition course today! 🩺🍓 #MedEd #FoodAsMedicine #FoodIsMedicine #MedEd

IPI+NIVO after prior PD1/L1 in HCC? ➡️Retrospective series, half tx w/ prior BEV/ATEZO (no prior anti-CTLA4) ➡️ORR 22% (7/32) ➡️All responders to late line IPI+NIVO had NONRESPONSE to prior PD1/L1 ncbi.nlm.nih.gov/pmc/articles/P…

Thrilled to welcome the newest class of hematology/medical oncology fellows to MD Anderson Cancer Center! Excited to work with all of you during training! #EndCancer

Join us in congratulating our resident physicians who are preparing to pursue advanced training through fellowship programs in their chosen specialty! UTSW Internal Medicine Chiefs Thomas Wang, MD @DinoKazi UTSW Media Relations 📷

👉👉👉Superb clinic & research teams working together in #TeamPemm clinic #leusm #BPDCN #MPNSM this month ! MD Anderson Cancer Center #endcancer | L➡️R Naveen Pemmaraju, MD Michelle Golez RNTerri Saenz RN Rhona Pinsoy RN Dr .Mir Lim Dr Kekejian, Rodney Haltom PA 🙌

Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic? Pan-RAS inhibitor shows early/deep molecular response (and 36% response rate) for G12X mutated pancreatic cancer. (Significant AEs: rash, diarrhea, nausea, vomiting) dailynews.ascopubs.org/do/pan-ras-inh…

#GI25 ASCO #LBA🌟 🚨CM8HW in dMMR #mCRC - the awaited nivo/ipi1 vs nivo PFS 🙌 📌 N=707 across all lines, 55% 1L, centrally confirmed 📌 PFS HR 0.62, p0.0003 👉3 yr PFS 68% v 51% 📌 ORR 71% vs 58% - PD 10% w/ combo 📌 safely reassuring🤙 ➡️nivo/ipi is the new SOC for dMMR

SOOOO proud of our MD Anderson Cancer Center med onc star fellows Michael LaPelusa, MD, Kelsey Pan, MD, MPH, & Mir Lim presenting their research today on #crcsm day at ASCO #GI25 ! Future is looking bright with their brilliant minds to #endcancer !

Dr. Dr. Marwan G. Fakih with P2 BOT/BAL study in refractory MSS mCRC w/o liver mets (vs TAS-102 or rego). BOT/BAL 75mg ORR 19% vs 0% SOC. Responses seem durable (data not yet mature). #GI25

Great data for pts w/ 2+ line met anal cancer for pembrolizumab+ficerafusp alfa (EGFR/TGFb bispecific) -ORR 29% & 41% 12-mo DFS=benefit in liver mets+pCR for exceptional responder ! Exciting signal as combination immuotherapy in anal cancer! MD Anderson Cancer Center #endcancer Bicara Therapeutics

#GI25 BREAKWATER Scott Kopetz changing the paradigm yet again! The true master of BRAF and colorectal targeted therapy. BRAF+ first line mCRC; n=236 on experimental arm Enco (BRAF) + Cetux (EGFR)+ FOLFOX ORR 60% vs 40%! OS not yet reached!!! Durable responses and twice as

Here’s the The Lancet publication! 📝 #GI25 OncoAlert thelancet.com/journals/lance…

#GI25 highlights #CommunityOnc: 1. #SCIENCE: Adv Eso SCC 2. #ESOPEC publication (Eso/GEJ/Ga) 3. Chemo in resectable Panc Ca 4. #StarterNET: GEP-NET 5. #CM8HW: dMMR/MSI-H mCRC 6. #BREAKWATER: BRAFV600E mCRC 7. ctDNA: #BESPOKE + SWOG80702 #OncTwitter #gism ASCO 1/8

6. #BREAKWATER: Ph 3, Enco + Cetux + mFOLFOX vs SoC in BRAFV600E mCRC - ORR 61% vs 40% - Interim OS at 12mos 79.5% vs 66% - Gr≥3 AEs: 37.7% vs 34.6% - New SoC for BRAFV600E 7/8

Grateful for the opportunity to work with the incredible Van Morris, MD on this phase I/II trial of encorafenib, cetuximab and nivolumab in pts with BRAF V600E mutated mCRC who progressed on prior treatment with BRAF + EGFR targeted tx. - While the addition of Nivo did not seem to

Just published in Journal of Clinical Oncology the updated ASCO guidelines on fertility preservation in people with #cancer: a must read for all colleagues involved in cancer care to increase awareness on #oncofertility issues OncoAlert Ann Partridge MD, MPH Oncofertility Link: ascopubs.org/doi/10.1200/JC…

Congratulations to the MD Anderson Cancer Center trainees who received 2025 Conquer Cancer, the ASCO Foundation Young Investigator and Merit Awards for their contributions to cancer research! Extremely grateful for your hard work and commitment to our mission to #EndCancer. So well-deserved!